Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study

Cancer Biomark. 2019;24(3):335-342. doi: 10.3233/CBM-181847.


Background: For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel.

Objective: We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients.

Methods: From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed.

Results: Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048).

Conclusion: Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.

Keywords: Biomarker; complement factor B; pancreatic cancer; prognosis; survival.

MeSH terms

  • Aged
  • Biomarkers, Tumor*
  • CA-19-9 Antigen / blood
  • Complement Factor B*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pancreatectomy
  • Pancreatic Neoplasms / blood*
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / mortality*
  • Pancreatic Neoplasms / surgery
  • Pilot Projects
  • Preoperative Period
  • Prognosis
  • ROC Curve
  • Retrospective Studies
  • Survival Analysis


  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • Complement Factor B